FDA advisory panel recommends allowing compounding of unapproved BPC-157 and KPV peptides

An FDA advisory panel narrowly voted to permit compounding pharmacies to produce BPC-157 and KPV, despite these peptides lacking formal FDA approval. This recommendation marks a significant shift in regulatory oversight for performance-enhancing and therapeutic substances, though the FDA is not legally bound to follow the panel's advice.